We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer.
- Authors
YASUYOSHI SATO; NAOKI FUKUDA; YU FUJIWARA; XIAOFEI WANG; TETSUYA URASAKI; AKIHIRO OHMOTO; KENJI NAKANO; MAKIKO ONO; JUNICHI TOMOMATSU; HIROKI MITANI; SHUNJI TAKAHASHI
- Abstract
Background/Aim: In the CheckMate-141 trial regarding head and neck cancer (HNC), nivolumab conferred a survival benefit to patients. However, the best treatment sequence of chemotherapy and anti-PD-1/PD-L1 therapy in these cancers is unclear. Patients and Methods: This was an observational study using data collected prospectively from 97 HNC patients treated with nivolumab at our institutions. Twenty-two HNC patients who received paclitaxel-based chemotherapy before (pre-PTX, n=12) and after (post-PTX, n=10) nivolumab were evaluated. Results: The median follow-up time was 15.9 months (range=6.9-35.9 months). There was a significant difference in the overall response rate (ORR) between pre-PTX (17%) and post-PTX (70%) (p=0.027). Similarly, time to progression (TTP) was significantly longer after nivolumab than before nivolumab (post-PTX, 7.4 months; pre-PTX, 4.9 months, p=0.020). Conclusion: Paclitaxel-based chemotherapy had a better ORR and TTP after nivolumab than before nivolumab for HNC. The sequential administration of anti-PD-1 therapy followed by paclitaxel-based chemotherapy could be a better strategy for HNC.
- Subjects
PACLITAXEL; CANCER chemotherapy; DISEASE progression; HEAD &; neck cancer; NIVOLUMAB
- Publication
In Vivo, 2021, Vol 35, Issue 2, p1211
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.12371